Characteristics of long-surviving patients with multiple myeloma: Over 12 years of follow-up in the Connect MM Registry.

person Howard R. Terebelo Providence Cancer Institute, Southfield, MI info_outline Howard R. Terebelo, James Omel, Lynne I. Wagner, James W. Hardin, Robert M. Rifkin, Sikander Ailawadhi, Brian G. Durie, Mohit Narang, Kathleen Toomey, Cristina J. Gasparetto, Prashant Ramesh Joshi, Edward Yu, E. Dawn Flick, Weiyuan Chung, Hans C. Lee, Rafat Abonour, Sundar Jagannath

Authors person Howard R. Terebelo Providence Cancer Institute, Southfield, MI info_outline Howard R. Terebelo, James Omel, Lynne I. Wagner, James W. Hardin, Robert M. Rifkin, Sikander Ailawadhi, Brian G. Durie, Mohit Narang, Kathleen Toomey, Cristina J. Gasparetto, Prashant Ramesh Joshi, Edward Yu, E. Dawn Flick, Weiyuan Chung, Hans C. Lee, Rafat Abonour, Sundar Jagannath Organizations Providence Cancer Institute, Southfield, MI, Myeloma Research Advocate/Advisor, Grand Island, NE, Wake Forest School of Medicine, Winston-Salem, NC, University of South Carolina, Columbia, SC, Rocky Mountain Cancer Centers, US Oncology Research, Denver, CO, Mayo Clinic, Jacksonville, FL, Cedars-Sinai Medical Center, Los Angeles, CA, US Oncology Research, Columbia, MD, Steeplechase Cancer Center, Somerville, NJ, Duke University Medical Center, Durham, NC, Bristol Myers Squibb, Summit, NJ, Bristol Myers Squibb, Princeton, NJ, The University of Texas MD Anderson Cancer Center, Department of Lymphoma/Myeloma, Houston, TX, Indiana University, Indianapolis, IN, Mount Sinai Hospital, New York, NY Abstract Disclosures Research Funding Pharmaceutical/Biotech Company Background: The Connect MM Registry is a large, US, multicenter, prospective observational cohort study of pts with newly diagnosed multiple myeloma (NDMM) and one of the largest, longest running MM registries. Long-term survivors (LTS), defined as patients (pts) who have ≥ 8 years of follow-up, comprise a large portion of the Connect MM Registry. The purpose of this analysis was to assess LTS demographic and clinical characteristics. Methods: Adult pts with NDMM (N = 3011) were enrolled from 250 community, academic, and government sites: Cohort 1 from 2009 – 2011 and Cohort 2 from 2012 – 2016. As 99% of LTS were enrolled in Cohort 1, only pts from Cohort 1 were included in this analysis. Pt data were unevaluable if there were missing treatments, disease assessments, or large gaps in activity during follow-up (n = 28). Baseline characteristics, treatment patterns, and quality of life (QoL) form completion rates were examined. Results: At data cutoff (5/17/21), of the 1493 pts in Cohort 1 with evaluable data, 279 were LTS and 1186 were non-LTS. LTS were generally younger and had better performance status at enrollment (Table). Most (66%) LTS received stem cell transplants and few experienced progression within the first 6 months (3%). Top first-line (1L) regimen for LTS was lenalidomide/bortezomib/dexamethasone (31%) vs bortezomib/dexamethasone (22%) in non-LTS. At data cutoff, 73% of LTS were still on treatment at their most recent visit. LTS underwent disease assessments more frequently (2.0 vs 1.3 per year) and had a higher QoL completion rate by year 5 (58% vs 46%). This analysis showed an estimated 8-year survival of 36% vs an observed 8-year survival of 39% from the SEER database. Additional analyses are ongoing. Conclusions: LTS were younger and healthier than non-LTS. Most LTS received triplets at induction, stem cell transplants in 1L, and were less likely to relapse within the first 6 months of treatment than non-LTS. These findings are consistent with what has been observed in MM clinical trials. Further, this analysis demonstrates the value of longitudinal data in the CONNECT MM Registry and provides insights on long surviving pts with MM. Clinical trial information: NCT01081028. Characteristic* Long-Term Survivors (n=279) Non-Long Term Survivors (n=1186) Age at informed consent, yr 62 68 Received SCT, n (%) 185 (66.3) 361 (30.4) ECOG PS < 2, % 66.3 56.9 Fast progression, n (%) † 8 (2.9) 84 (7.1) Visits/yr, n 3.5 3.0 Disease assessments/yr, n 2.0 1.3 New lines of therapy/yr, n 0.2 0.6 QoL questionnaire completion rate at baseline, % 96.7 94.2 QoL questionnaire completion rate at 5 yrs, % 58.4 45.6 No evidence of treatment in most recent yr of follow-up, n (%) 5 (1.8) — ECOG PS, Eastern Cooperative Oncology Group performance status; QoL, quality of life; SCT, stem cell transplant.*All continuous variables reported as medians. † Defined as having progressed ≤ 6 months of start of 1L. Among patients with at least one line of therapy.